TY - JOUR
T1 - Atopic Dermatitis in America Study
T2 - A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population
AU - Chiesa Fuxench, Zelma C.
AU - Block, Julie K.
AU - Boguniewicz, Mark
AU - Boyle, John
AU - Fonacier, Luz
AU - Gelfand, Joel M.
AU - Grayson, Mitchell H.
AU - Margolis, David J.
AU - Mitchell, Lynda
AU - Silverberg, Jonathan I.
AU - Schwartz, Lawrence
AU - Simpson, Eric L.
AU - Ong, Peck Y.
N1 - Funding Information:
Atopic Dermatitis in America is an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association sponsored by Sanofi Genzyme and Regeneron.
Publisher Copyright:
© 2018 The Authors
PY - 2019/3
Y1 - 2019/3
N2 - Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9–8.8). Overall, 60.1% (56.1–64.1) of participants were classified as having mild, 28.9% (25.3–32.7) as having moderate, and 11% as having severe (8.6–13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients = 4.71 [6.44] vs. control individuals = 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard deviation] for AD patients = 7.03 [4.80] vs. control individuals = 4.73 [4.8]) and depression (mean, [standard deviation] for AD patients = 5.83 [4.54] vs. control individuals = 3.62 [3.61]) scales, indicating a worse impact on quality of life and an increased likelihood of anxiety or depression. Based on our prevalence estimates, 16.5 million adults would have a diagnosis of atopic dermatitis, with 6.6 million meeting criteria for moderate to severe disease. Our study confirms the high prevalence and disease burden of atopic dermatitis in this population.
AB - Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9–8.8). Overall, 60.1% (56.1–64.1) of participants were classified as having mild, 28.9% (25.3–32.7) as having moderate, and 11% as having severe (8.6–13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients = 4.71 [6.44] vs. control individuals = 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard deviation] for AD patients = 7.03 [4.80] vs. control individuals = 4.73 [4.8]) and depression (mean, [standard deviation] for AD patients = 5.83 [4.54] vs. control individuals = 3.62 [3.61]) scales, indicating a worse impact on quality of life and an increased likelihood of anxiety or depression. Based on our prevalence estimates, 16.5 million adults would have a diagnosis of atopic dermatitis, with 6.6 million meeting criteria for moderate to severe disease. Our study confirms the high prevalence and disease burden of atopic dermatitis in this population.
UR - http://www.scopus.com/inward/record.url?scp=85061536526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061536526&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2018.08.028
DO - 10.1016/j.jid.2018.08.028
M3 - Article
C2 - 30389491
AN - SCOPUS:85061536526
SN - 0022-202X
VL - 139
SP - 583
EP - 590
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 3
ER -